Baillie Gifford Amends Ginkgo Bioworks Stake (SC 13G/A)
Ticker: DNABW · Form: SC 13G/A · Filed: Jan 29, 2024 · CIK: 1830214
| Field | Detail |
|---|---|
| Company | Ginkgo Bioworks Holdings, Inc. (DNABW) |
| Form Type | SC 13G/A |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, SC-13G, biotechnology
Related Tickers: DNA
TL;DR
**Baillie Gifford updated its Ginkgo Bioworks stake, signaling continued institutional interest.**
AI Summary
Baillie Gifford & Co, a major investment management firm, has updated its ownership stake in Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) as of December 29, 2023. This Amendment No. 4 to their Schedule 13G filing indicates a change in their beneficial ownership, which is important for investors as large institutional holdings can influence stock stability and investor confidence. While the exact percentage change isn't detailed in the provided text, the filing confirms their continued significant interest in the synthetic biology company.
Why It Matters
Large institutional investors like Baillie Gifford & Co holding or adjusting their positions can signal confidence or concern, potentially impacting Ginkgo Bioworks' stock price and perceived stability.
Risk Assessment
Risk Level: low — This filing is a routine update of an institutional ownership stake and does not inherently indicate high risk.
Analyst Insight
Investors should note that a prominent institutional investor like Baillie Gifford & Co continues to hold a position in Ginkgo Bioworks, which can be a positive signal for long-term stability, but should also investigate the specific changes in ownership percentage (not detailed in this excerpt) for a complete picture.
Key Numbers
- 37611X100 — CUSIP Number (identifies Ginkgo Bioworks Holdings, Inc. Class A Common Stock)
- 20240129 — Filed As Of Date (the date the SC 13G/A was officially filed)
- 20231229 — Date of Event (the date of the ownership change that triggered the filing)
- 005-92710 — SEC File Number (identifies Ginkgo Bioworks Holdings, Inc. with the SEC)
Key Players & Entities
- Baillie Gifford & Co (company) — the investment management firm filing the SC 13G/A
- Ginkgo Bioworks Holdings, Inc. (company) — the subject company whose Class A Common Stock is being reported
- December 29, 2023 (date) — the date of the event requiring the filing
- Amendment No. 4 (number) — the specific amendment number to the Schedule 13G filing
- 0001088875-24-000032 (number) — the accession number for the filing
Forward-Looking Statements
- Baillie Gifford & Co will maintain a significant, long-term stake in Ginkgo Bioworks Holdings, Inc. (Baillie Gifford & Co) — medium confidence, target: 2025-12-31
FAQ
What type of filing is this document?
This document is an 'SC 13G/A', which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE' and 'CONFORMED SUBMISSION TYPE' fields.
Who is the filer of this SC 13G/A?
The filer of this SC 13G/A is 'BAILLIE GIFFORD & CO', as indicated under the 'FILED BY' section of the filing.
What is the subject company of this filing?
The subject company is 'Ginkgo Bioworks Holdings, Inc.', as stated under the 'SUBJECT COMPANY' section and in the title of the Schedule 13G.
What is the specific date of the event that required this filing?
The date of the event which requires filing of this statement is '29 December 2023', as explicitly stated in the Schedule 13G form.
Under which rule is this Schedule 13G/A filed?
This Schedule 13G/A is filed under 'Rule 13d-1(b)', as indicated by the checked box 'X' on the form.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 29, 2024 regarding Ginkgo Bioworks Holdings, Inc. (DNABW).